Botulinum Toxin Type A0 vendors competing
No vendor pricing available for this peptide yet.
Research details
Botulinum Toxin Type A — research data
Half-lifeClinical effect: 3–4 months. Toxin cleaved by cellular proteases over weeks; nerve terminal regeneration restores function.
Regulatory statusFDA-approved (Botox)
NCAA D1Permitted
Overview
About Botulinum Toxin Type A
Mechanism of action
Clostridium botulinum-derived neurotoxin; cleaves SNAP-25 protein in presynaptic terminal; prevents acetylcholine vesicle fusion and release; causes temporary, reversible muscle paralysis/relaxation at injection site.
Safety profile
Injection site pain/bruising; asymmetry if incorrectly placed; ptosis (drooping eyelid/brow); headache; rare: dysphagia, flu-like symptoms, spread of toxin effect. Requires trained administration. · Decades of clinical use; extremely well-characterized; rare distant spread of toxin effect
Related pages